Anthem BCBSLow ImpactAdministrative
[New York] Lenalidomide is now available with end‑to‑end REMS support
Published May 3, 2026
AI Summary
Anthem New York now provides end-to-end REMS (Risk Evaluation and Mitigation Strategy) support for lenalidomide, a cancer medication. This streamlines the complex safety monitoring and dispensing process for providers prescribing this high-risk oncology drug.
Action Required
Oncology practices prescribing lenalidomide should contact Anthem New York to understand the new REMS support process and how it may streamline patient access and safety monitoring requirements.
Plan Types
Commercial
States
NY
Specialties
oncology, hematology